Top CFO Executive Search Firm in Bengaluru for Pharma & Biotech — 2026

Pharma and biotech finance in Bengaluru is shaped by long, capital-hungry development cycles and global regulation. A biotech or biosimilars CFO must fund multi-year programmes that consume capital long before revenue — managing R&D capitalisation, milestone and grant accounting, dilution and patient capital — while building the controls a global-regulator-facing, often listed business demands. A CRO or CDMO CFO must run capacity, client-contract and capex economics for a business serving global pharma under audit. The defining scarcity is the finance leader who is comfortable with the science and the long cycle, can raise and steward development capital, and holds USFDA-grade financial controls.

Compensation blends a cash base with milestone- and approval-linked incentives and, in venture- or listed-biotech settings, equity tied to development milestones. The brief sets this out. The stakeholder map runs from scientific and R&D leadership and investors to auditors and, for CRO/CDMO, global pharma clients. References reach to investors, auditors and scientific-finance peers, because the question that decides these mandates — can this CFO fund the science and hold the controls — is answered by those who have watched them through a cycle.